Alkermes’ up to $2.1B Purchase of Avadel Sets Groundwork for ‘Strategic Evolution’

With Avadel under its fold, Alkermes expects to accelerate its expansion into the sleep market, laying the foundation for its late-stage narcolepsy asset alixorexton.